Genmab’s U.S.-listed ADRs traded lower as the market continued to reprice pipeline risk after the company’s decision to discontinue further clinical development of acasunlimab, a late-stage immuno-oncology asset that had been in Phase 3 testing. That portfolio decision removes a potential future growth pillar and shifts investor focus back to the remaining late-stage slate and commercial execution for epcoritamab (EPKINLY/TEPKINLY) and other partnered assets. (ir.genmab.com)

Sentiment has also been pressured by mixed late-stage outcomes around epcoritamab: a Phase 3 study in DLBCL missed its primary endpoint of overall survival, which can weigh on expectations for label expansion and prescribing momentum even when other endpoints and commercial progress remain constructive. Separately, recent disclosures have highlighted continued clinical development elsewhere in the pipeline, but today’s price action suggests investors are prioritizing uncertainty and headline risk over longer-dated optionality. (fiercepharma.com)

The next near-term focal point is the upcoming quarterly results window (with market calendars pointing to mid-May 2026), when investors will look for any update to outlook, R&D spend priorities after portfolio pruning, and commercial trajectory for epcoritamab-based regimens. Any incremental clarity on regulatory timing and how Genmab reallocates resources after stopping acasunlimab is likely to matter more than routine conference participation. (zacks.com)